---
title: treatment of myelodysplastic syndromes
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[myelodysplastic syndromes]]

# treatment of myelodysplastic syndromes

must read: [[clinical_decision-making_and_treatment_of_myelodysplastic_syndromes.md|Clinical decision-making and treatment of myelodysplastic syndromes]]

(Am J Hematol 2012;87:692): intensity based on IPSS-R (qv), age, performance status (PS)

- Poor PS, any risk
  â†’ supportive care (transfusions, G-CSF, Epo, TPO-mimetic, abx prn)

- Very low/low risk (IPSS-R)
  â†’ ESA if Epo <500; lenalidomide (esp. for 5q synd.; Blood 2011;118:3765); luspatercept (MDS-RS). TPO-mimetic agents, transfusions.

- Interm/high risk (IPSS-R)
  â†’ allogeneic HSCT if medically fit
  DNA **methyl**-transferase inh : [[hypomethylating agents|HMA]]
  - aza-CI-tadine subcutaneous
  - de-CI-tabine IV (Lancet Oncol 2009;10:223)
  - oral decitabine/cedazuridine

## Hypoplastic MDS çš„æ²»ç™‚æ–¹æ¡ˆæ˜¯ä»€éº¼ï¼Ÿ

- æ‘˜è¦ï¼šHypoplastic MDS çš„æ²»ç™‚æ–¹æ¡ˆåŒ…æ‹¬å…ç–«æŠ‘åˆ¶æ²»ç™‚ï¼ˆCsAï¼ŒATGï¼‰å’Œé€ è¡€å¹¹ç´°èƒžç§»æ¤ï¼ˆHSCTï¼‰ã€‚
- åŽŸæ–‡ï¼šHypoplastic MDS (rare) â†’ consider immunosuppression (CsA, ATG), HSCT
